Valuation: Collegium Pharmaceutical, Inc.

Market Cap 711M 616M 582M 527M 990M 68.2B 997M 6.95B 2.67B 34.58B 2.67B 2.61B 110B P/E 2026 *
10.8x
P/E 2027 * 5.6x
Enterprise Value 711M 616M 582M 527M 990M 68.2B 997M 6.95B 2.67B 34.58B 2.67B 2.61B 110B EV / Sales 2026 *
0.85x
EV / Sales 2027 * 0.84x
Free-Float
77.39%
Yield 2026 *
-
Yield 2027 * -
1 day-4.25%
1 week-6.55%
Current month-11.26%
1 month-22.64%
3 months-36.12%
6 months-36.70%
Current year-52.83%
1 week 21.65
Extreme 21.6501
23.45
1 month 21.65
Extreme 21.6501
29.65
Current year 21.65
Extreme 21.6501
49.31
1 year 21.65
Extreme 21.6501
50.79
3 years 20.95
Extreme 20.95
50.79
5 years 14.04
Extreme 14.04
50.79
10 years 7.37
Extreme 7.37
50.79
Manager TitleAgeSince
Chief Executive Officer 51 2024-11-11
Director of Finance/CFO 50 2021-05-23
Chief Tech/Sci/R&D Officer 65 2022-03-22
Director TitleAgeSince
Chairman 69 2025-05-14
Director/Board Member 72 2014-01-31
Director/Board Member 78 2014-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
5/18/26 Sell

Director

-20 0.0001%
5/15/26 Exercice

Director

21,527 0.0664%
5/14/26 Free

Director

8,741 0.0270%
Change 5-day change 1-year change 3-year change Capi.($)
-4.25%-6.55%-37.46%-3.58% 711M
-0.19%+1.09%+51.85%+97.36% 1,013B
+0.33%-0.71%+50.62%+65.50% 644B
+0.49%+5.73%+20.88%+72.92% 465B
+0.54%+4.14%+40.13%+40.38% 352B
+1.10%+3.19%+18.93%+25.21% 264B
+0.75%+4.82%+7.63%+13.83% 253B
-1.53%-4.46%+36.90%+44.08% 203B
+0.67%-4.14%-22.88%-57.42% 188B
-0.08%-0.23%+30.00%+93.34% 181B
Average -0.05%-1.28%+19.66%+39.16% 356.44B
Weighted average by Cap. +0.30%+0.01%+34.92%+60.06%

Financials

2026 *2027 *
Net sales 836M 724M 685M 620M 1.16B 80.2B 1.17B 8.17B 3.14B 40.67B 3.14B 3.07B 130B 843M 730M 690M 625M 1.17B 80.82B 1.18B 8.24B 3.17B 40.98B 3.16B 3.09B 131B
Net income 72.55M 62.84M 59.42M 53.8M 101M 6.96B 102M 709M 273M 3.53B 273M 266M 11.25B 151M 131M 124M 112M 211M 14.53B 212M 1.48B 570M 7.37B 569M 556M 23.5B
Net Debt - -
Logo Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. Its portfolio also includes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD in people six years of age and older.
Employees
423
Date Price Change Volume
26-09-15 $21.84 -4.25% 954,003
26-09-14 $22.81 +0.26% 825,547
26-09-11 $22.75 -0.74% 661,300
26-09-10 $22.92 -1.88% 889,098
26-09-09 $23.36 -0.04% 1,077,597
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
21.84USD
Average target price
48.86USD
Spread / Average Target
+123.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COLL Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!